Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)

Correction to: Genetics in Medicine 2022; https://doi.org/10.1016/j.gim.2022.11.004, published online 16 December 2022. In the article “Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)” by Dungan JS et al (Genet Med 2023;25:100336), the following updates were made. After publication of this Guideline, ACMG decided to change the term for this screening from “non-invasive prenatal screening”, and its corresponding acronym, to “prenatal cell-free DNA screening”. Future ACMG publications about this topic will now include the revised terminology. On page 4 (left-hand column), the sentence “Corresponding FPR for those trisomies are 0.07% (95% CI = 0.03%-0.17%) and 0.04% (95% CI = 0.02%-0.08%), respectively (Table 3 in Rose et al).3” was updated to “Corresponding FPR for those trisomies are 0.07% (95% CI = 0.03%-0.17%) and 0.04% (95% CI = 0.02%-0.08%), respectively (Table 1 in Rose et al).3” On page 12, reference 43 was updated to “43. Rousseau F, Langlois S, Johnson J, et al. Prospective head-to-head comparison of accuracy of two sequencing platforms for screening for fetal aneuploidy by cell-free DNA: the PEGASUS study. Eur J Hum Genet. 2019;27(11):1701-1715. http://doi.org/10.1038/s41431-019-0443-0”. The authors would like to apologize for any inconvenience this may have caused. The article has been corrected online and can be accessed at https://doi.org/10.1016/j.gim.2022.11.004. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)Genetics in MedicineVol. 25Issue 2PreviewThis workgroup aimed to develop an evidence-based clinical practice guideline for the use of noninvasive prenatal screening (NIPS) for pregnant individuals at general risk for fetal trisomy 21, trisomy 18, or trisomy 13 and to evaluate the utility of NIPS for other chromosomal disorders. Full-Text PDF